Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation A first-in-class, first-in-human Phase I trial of KPT-330, a Selective Inhibitor of Nuclear Export (SINE) in patients (pts) with advanced solid tumors PDF (2.94 MB) Read More Paper CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma External Link Read More Paper CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications External Link Read More Presentation Targeted inhibition of Chromosomal Maintenance Region Protein (CRM1) potently suppresses growth of human neuroblastoma cell line models PDF (1.41 MB) Read More Paper Prognostic impact and targeting of CRM1 in acute myeloid leukemia External Link Read More Paper KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia External Link Read More Paper Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells External Link Read More Paper Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma External Link Read More Paper Consensus Induced Fit Docking (cIFD): methodology, validation, and application to thediscovery of novel Crm1 inhibitors External Link Read More Paper CRM1 Blockade by Selective Inhibitors of Nuclear Export (SINE) attenuates Kidney Cancer Growth External Link Read More Previous 1 … 18 19 20 21 Next